Wayne Nicole, Singamneni Venkata S, Venkatesh Rasika, Cherlin Tess, Verma Shefali S, Guerraty Marie A
Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Microcirculation. 2025 Jan;32(1):e12896. doi: 10.1111/micc.12896.
Coronary microvascular disease (CMVD) affects the coronary pre-arterioles, arterioles, and capillaries and can lead to blood supply-demand mismatch and cardiac ischemia. CMVD can present clinically as ischemia or myocardial infarction with no obstructive coronary arteries (INOCA or MINOCA, respectively). Currently, therapeutic options for CMVD are limited, and there are no targeted therapies. Genetic studies have emerged as an important tool to gain rapid insights into the molecular mechanisms of human diseases. For example, coronary artery disease (CAD) genome-wide association studies (GWAS) have enrolled hundreds of thousands of patients and have identified > 320 loci, elucidating CAD pathogenic pathways and helping to identify therapeutic targets. Here, we review the current landscape of genetic studies of CMVD, consisting mostly of genotype-first approaches. We then present the hypothesis that CAD GWAS have enrolled heterogenous populations and may be better characterized as ischemic heart disease (IHD) GWAS. We discuss how several of the genetic loci currently associated with CAD may be involved in the pathogenesis of CMVD. Genetic studies could help accelerate progress in understanding CMVD pathophysiology and identifying putative therapeutic targets. Larger phenotype-first genomic studies into CMVD with adequate sex and ancestry representation are needed. Given the extensive CAD genetic and functional validation data, future research should leverage these loci as springboards for CMVD genomic research.
冠状动脉微血管疾病(CMVD)累及冠状动脉前小动脉、小动脉和毛细血管,可导致供需不匹配和心肌缺血。CMVD在临床上可表现为无阻塞性冠状动脉的心肌缺血或心肌梗死(分别为INOCA或MINOCA)。目前,CMVD的治疗选择有限,且尚无靶向治疗方法。基因研究已成为快速洞察人类疾病分子机制的重要工具。例如,冠状动脉疾病(CAD)全基因组关联研究(GWAS)已纳入数十万名患者,并确定了320多个位点,阐明了CAD的致病途径并有助于确定治疗靶点。在此,我们综述了CMVD基因研究的现状,这些研究大多采用先基因型的方法。然后,我们提出一个假设,即CAD GWAS纳入的是异质性人群,或许更应被描述为缺血性心脏病(IHD)GWAS。我们讨论了目前与CAD相关的几个基因位点可能如何参与CMVD的发病机制。基因研究有助于加快对CMVD病理生理学的理解,并确定潜在的治疗靶点。需要针对CMVD开展更大规模的、具有足够性别和血统代表性的先表型基因组研究。鉴于CAD有广泛的基因和功能验证数据,未来的研究应利用这些位点作为CMVD基因组研究的跳板。